These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30029970)

  • 21. Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome.
    Roche N; Rabbat A; Zureik M; Huchon G
    Curr Opin Pulm Med; 2010 Mar; 16(2):112-7. PubMed ID: 20019614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Authors response. The chronic obstructive pulmonary disease (COPD) control panel: towards personalised medicine in COPD.
    Agusti A; MacNee W
    Thorax; 2013 Apr; 68(4):389-90. PubMed ID: 23593649
    [No Abstract]   [Full Text] [Related]  

  • 23. How should we define and classify exacerbations in chronic obstructive pulmonary disease?
    Trigueros Carrero JA
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):33-41. PubMed ID: 23551022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early identification of exacerbations in patients with chronic obstructive pulmonary disease.
    Yawn BP
    J Prim Care Community Health; 2013 Jan; 4(1):75-80. PubMed ID: 23799693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD.
    Kang HS; Rhee CK; Kim SK; Kim JW; Lee SH; Yoon HK; Ahn JH; Kim YH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2467-2473. PubMed ID: 27757029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Acute Exacerbation of Asthma and Chronic Obstructive Pulmonary Disease in the Emergency Department.
    Suau SJ; DeBlieux PM
    Emerg Med Clin North Am; 2016 Feb; 34(1):15-37. PubMed ID: 26614239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
    Jones PW; Agusti AG
    Eur Respir J; 2006 Apr; 27(4):822-32. PubMed ID: 16585091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de Pneumologie de Langue Française (Argumentary)].
    Jouneau S; Roche N
    Rev Mal Respir; 2017 Apr; 34(4):323-326. PubMed ID: 28502518
    [No Abstract]   [Full Text] [Related]  

  • 29. The quality of medical care during an acute exacerbations of chronic obstructive pulmonary disease.
    Pradan L; Ferreira I; Postolache P
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(4):870-4. PubMed ID: 24502063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Consensus on integrated care of acute exacerbations of chronic obstructive pulmonary disease (ATINA-EPOC). Part III].
    Arnedillo Muñoz A
    Semergen; 2012 Oct; 38(7):452-5. PubMed ID: 23021578
    [No Abstract]   [Full Text] [Related]  

  • 31. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
    Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
    Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New guidelines for acute COPD exacerbations.
    Jouneau S; Chabot F; Roche N
    Rev Mal Respir; 2017 Apr; 34(4):279-281. PubMed ID: 28599784
    [No Abstract]   [Full Text] [Related]  

  • 33. Sex and Gender Omic Biomarkers in Men and Women With COPD: Considerations for Precision Medicine.
    DeMeo DL
    Chest; 2021 Jul; 160(1):104-113. PubMed ID: 33745988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.
    Yohannes AM; Mülerová H; Lavoie K; Vestbo J; Rennard SI; Wouters E; Hanania NA
    J Am Med Dir Assoc; 2017 Nov; 18(11):955-959.e6. PubMed ID: 28733182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia.
    Duman D; Aksoy E; Agca MC; Kocak ND; Ozmen I; Akturk UA; Gungor S; Tepetam FM; Eroglu SA; Oztas S; Karakurt Z
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2469-78. PubMed ID: 26648709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Name of COPD: Semiotics and Precision.
    Bustamante V; Urrutia I
    Arch Bronconeumol; 2016 Oct; 52(10):503-4. PubMed ID: 27350437
    [No Abstract]   [Full Text] [Related]  

  • 37. Introduction to precision medicine in COPD.
    Leung JM; Obeidat M; Sadatsafavi M; Sin DD
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30679189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Appropriate investigations during an acute COPD exacerbation requiring hospitalization].
    Jébrak G
    Rev Mal Respir; 2017 Apr; 34(4):375-381. PubMed ID: 28499638
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of exacerbations on respiratory system impedance measured by a forced oscillation technique in COPD: a prospective observational study.
    Kamada T; Kaneko M; Tomioka H
    Int J Chron Obstruct Pulmon Dis; 2017; 12():509-516. PubMed ID: 28223791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.
    Montes de Oca M; Aguirre C; Lopez Varela MV; Laucho-Contreras ME; Casas A; Surmont F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3059-3067. PubMed ID: 27994446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.